Refractory Tumors Recruiting Phase 2 Trials for DB00072 (Trastuzumab)

Also known as: Refractory Tumor

IndicationStatusPhase
DBCOND0036368 (Refractory Tumors)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03239015Efficacy and Safety of Targeted Precision Therapy in Refractory Tumor With Druggable Molecular EventTreatment